Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia-Reference-Cited by-同舟云学术

Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia

Published:2008-05-06 Issue:12 Volume:62 Page:1864-1869
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:

Author:

Bogazzi F.,Buralli S.,Manetti L.,Raffaelli V.,Cigni T.,Lombardi M.,Boresi F.,Taddei S.,Salvetti A.,Martino E.

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2008.01779.x/fullpdf

Reference28 articles.

1. Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemic men and women;Colao;Nat Clin Pract Endocrinol Metab,2006

2. Evidence-based medical review update: pharmacological and surgical treatment of Parkinson’s disease: 2001 to 2004;Goetz;Mov Disord,2005

3. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivate, in hyperprolactinemic patients;Ciccarelli;J Clin Endocrinol Metab,1989

4. Dopamine receptor agonists for treating prolactinomas;Colao;Expert Opin Investig Drugs,2002

5. Pregnancy outcome after cabergoline treatment in early weeks of gestation;Ricci;Reprod Toxicol,2002

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins;Journal of Psychopharmacology;2024-01-12

2. Approach to the Patient With Prolactinoma;The Journal of Clinical Endocrinology & Metabolism;2023-03-28

3. Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints;The Journal of Clinical Endocrinology & Metabolism;2020-11-28

4. Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis;Heart;2019-05-25

5. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology;Echo Research and Practice;2019-03